Simple LC-MS/MS methods for simultaneous determination of pitavastatin and its lactone metabolite in human plasma and urine involving a procedure for inhibiting the conversion of pitavastatin lactone to pitavastatin in plasma and its application to a pharmacokinetic study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 72, Issue , 2013, Pages 8-15

  Qi, Xiemin ^a   Ding, Li ^a   Wen, Aidong ^b   Zhou, Na ^a   Du, Xiaolang ^a   Shakya, Shailendra ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Interconversion; LC ESI MS MS; Pharmacokinetics; Pitavastatin; Pitavastatin lactone; Stability

Indexed keywords

BUFFER; DRUG METABOLITE; LACTONE; PITAVASTATIN; PITAVASTATIN LACTONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; ELECTROSPRAY; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; QUALITY CONTROL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; VALIDATION PROCESS;

ADMINISTRATION, ORAL; CALIBRATION; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; LACTONES; MALE; QUINOLINES; REFERENCE STANDARDS; TANDEM MASS SPECTROMETRY;

EID: 84869029040     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.09.026     Document Type: Article

References (25)

1. Saito Y., Yamada N., Teramoto T., Itakura H., Hata Y., Nakaya N., Mabuchi H., Tushima M., Sasaki J., Ogawa N., Goto Y. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolaemia. Atherosclerosis 2002, 162:373-379.
2. Tonkin A., Aylward P., Colquhoun D., Glasziou P., Harris P., MacMahon S., Magnus P., Newel D., Nestel P., Sharpe N., Hunt D., Shaw J., Simes R.J., Thompson P., Thomson A., West M., White H., Simes S., Hague W., Caleo S., Hall J., Martin A., Mulray S., Barter P., Beilin L., Collins R., McNeil J., Meier P., Willimott H., Smithers D., Wallace P., Sullivan D., Keech A. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 1998, 339:1349-1357.
3. Havel R.J., Rapaport E. Management of primary hyperlipidemia. N. Engl. J. Med. 1995, 332:1491-1498.
4. Yamada I., Fujino H., Shimada S., Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans. Xenobiotica 2003, 33:789-803.
5. Fujino H., Yamada I., Shimada S., Yoneda M., Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyl-transferase enzymes involved in lactonization. Xenobiotica 2003, 33:27-41.
6. Fujino H., Yamada I., Shimada S., Kojima J. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase-effect of Cmoat deficiency on hepatobiliary excretion in rats and of mdr 1 a/b gene disruption on tissue distribution in mice. Drug. Metab. Pharmacokinet. 2002, 17:449-456.
7. Lv H., Sun J.G., Wang G.J., Zhu X.Y., Zhang Y., Gu S.H., Liang Y., Sun J. Determination of pitavastatin in human plasma via HPLC-ESI-MS/MS and subsequent application to a clinical study in healthy Chinese volunteers. Clin. Chim. Acta 2007, 386:25-30.
8. Di B., Su M.X., Yu F., Qu L.J., Zhao L.P., Cheng M.C., He L.P. Solid-phase extraction and liquid chromatography/tandem mass spectrometry assay for the determination of pitavastatin in human plasma and urine for application to phase I clinical pharmacokinetic studies. J. Chromatogr. B 2008, 868:95-101.
9. Wen J.H., Xiong Y.Q. Determination of the concentration of pitavastatin in human plasma by LC-MS and subsequent application to a clinical study. Chin. JMAP 2010, 27:62-65.
10. Qiu C., Zhang M., Liu X., Wen Y.G. The research of pharmacokinetics of pitavastatin in healthy volunteers. Pharm. Care Res. 2009, 9:225-227.
11. Deng C., Yi T., Tang L., Li Y.J. A simple and sensitive LC-MS/MS method for determining the concentration of pitavastatin in human plasma. Chin. J. New Drug 2009, 18:1113-1115.
12. Chen C.X., Li G.W., Wen Y.G. Rapid determination of pitavastatin in plasma by LC-ESI-MS/MS. Chin. JMAP 2010, 27:642-645.
13. Shen-Tu J.Z., Xu X., Liu J., Hu X.J., Chen J.C., Wu L.H., Huang M.Z., Zhou H.L. Determination of pitavastatin in human plasma by LC-MS-MS. J. Chromatogr. 2009, 69:1041-1047.
14. Chen Y., Tan Z.R., Zhou G., Ou-Yang D.S., Zhang J., Zhou H.H. LC-MS determination of pitavastatin in human plasma and its application. J. Clin. Pharmacol. 2011, 46:134-137.
15. Deng J.W., Kim K.B., Song I.S., Shon J.H., Zhou H.H., Liu K.H., Shin J.G. Determination of two HMG-CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography-tandem mass spectrometry for pharmaceutical study. Biomed. Chromatogr. 2008, 22:131-135.
16. Fujino H., Kojima J., Yamada Y., Kanda H., Kimata H. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA Reductase (4): interspecies variation in laboratory animals and humans. Xenobio. Metabol. Dispos. 1999, 14:79-91.
17. Kojima J., Fujino H., Yosimura M., Morikawa H., Kimata H. Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. J. Chromatogr. B 1999, 724:173-180.
18. Hui C.K., Cheung B.M.Y., Lau G.K.K. Pharmacokinetics of pitavastatin in subjects with child - Pugh A and B cirrhosis. Br. J. Clin. Pharmacol. 2004, 59:291-297.
19. Tian L., Huang Y.L., Jia Y.H., Hua L., Li Y.S. Development and validation of a liquid chromatography-tandem mass spectrometric assay for pitavastatin and its lactone in human plasma and urine. J. Chromatogr. B 2008, 865:127-132.
20. Ashwini O., Swati G., Chintan V., Harish P. Determination of pitavastatin from human plasma using high performance liquid chromatography with fluorescence detection. Chin. J. Chromatogr. 2007, 25:715-718.
21. Wang L.L., Chen X.Y., Song B., Zhang Y.F., Zhong D.F. Determination of pitavastatin in human plasma by liquid chromatography-tandem mass spectrometry. Chin. J. New Drugs Clin. Rem. 2007, 26:805-808.
22. Zhu H., Ding L., Shakya S., Qi X.M., Hu L.L., Yang X.L., Yang Z.L. Simultaneous determination of asperosaponin VI and its active metabolite hederagenin in rat plasma by liquid chromatography-tandem mass spectrometry with positive/negative ion-switching electrospray ionization and its application in pharmacokinetic study. J. Chromatogr. B 2011, 30:3407-3414.
23. Zhao Y.R., Ding L., Fan H.W., Yu Y., Qi X.M., Leng Y., Rao Y.K. Determination of the unstable drug otilonium bromide in human plasma by LC-ESI-MS and its application to a pharmacokinetic study. J. Chromatogr. B 2010, 878:2896-2900.
24. Kojima J., Fujino H., Abe H., Yosimura M., Kanda H., Kimata H. Identification of metabolites of NK-104, an HMG-CoA reductase inhibitor, in rat, rabbit and dog bile. Biol. Pharm. Bull. 1999, 22:142-150.
25. Wen J., Xiong Y. OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J. Clin. Pharm. Ther. 2010, 35:99-104.